An economic evaluation of erythropoiesis-stimulating agents in CKD

American Journal of Kidney Diseases

Volumn 56, Issue 6, 2010, Pages 1050-1061

  Clement, Fiona M ^a,b   Klarenbach, Scott ^c   Tonelli, Marcello ^c   Wiebe, Natasha ^c   Hemmelgarn, Brenda ^a,b   Manns, Braden J ^a,b,d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d FOOTHILLS HOSPITAL   (Canada)

Author keywords

Chronic kidney disease; Economic evaluation; Erythropoiesis stimulating agents; Hemoglobin targets

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; ERYTHROPOIESIS; FEMALE; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE;

AGED; AGED, 80 AND OVER; ANEMIA; CHRONIC DISEASE; COHORT STUDIES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RENAL DIALYSIS;

EID: 78649420110     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2010.07.015     Document Type: Article

References (61)

1. A. Besarab, W.K. Bolton, and J.K. Browne The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 9 1998 584 590
2. T.B. Drueke, F. Locatelli, N. Clyne CREATE Investigators Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 2006 2071 2084
3. A.K. Singh, L. Szczech, K.L. Tang CHOIR Investigators Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2006 2085 2098
4. National Kidney Foundation KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 update of hemoglobin target Am J Kidney Dis 50 3 2007 471 530
5. A. Piccoli, R.M. Puggia, M. Fusaro, E. Favaro, and L. Pillon A decision analysis comparing three dosage regimens of subcutaneous epoetin in continuous ambulatory peritoneal dialysis Pharmacoeconomics 7 5 1995 444 456
6. D.M. Hynes, K.T. Stroupe, and J.W. Greer Potential cost savings of erythropoietin administration in end-stage renal disease Am J Med 112 3 2002 169 175
7. M. Tonelli, W.C. Winkelmayer, K.K. Jindal, W.F. Owen, and B.J. Manns The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients Kidney Int 64 1 2003 295 304
8. Canadian Agency for Drugs and Technologies in Health Guidelines for the Economic Evaluation of Health Technologies 3rd ed. 2006 Canadian Agency for Drugs and Technologies in Health Ottawa, Canada
9. Canadian Institute for Health Information Treatment of End-Stage Organ Failure in Canada, 1995-2004 2006 Annual Report 2006 Canadian Institute for Health Information Ottawa, Canada
10. D. Cournoyer, E.B. Toffelmire, G.A. Wells, D.L. Barber, B.J. Barrett, and R. Delage Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk J Am Soc Nephrol 15 10 2004 2728 2734
11. J. Bahlmann, K.H. Schoter, and P. Scigalla Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study Contrib Nephrol 88 1991 90 106
12. W.M. Bennett A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease J Am Soc Nephrol 1 7 1991 990 998
13. Canadian Erythropoietin Study Group Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients BMJ 300 1990 573 578
14. R.N. Foley, P.S. Parfrey, and J. Morgan Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy Kidney Int 58 2000 1325 1335
15. H. Furuland, T. Linde, J. Ahlmen, A. Christensson, U. Strombom, and B.G. Danielson A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients Nephrol Dial Transplant 18 2003 353 361
16. C. Gouva, P. Nikolopoulos, J.P.A. Ioannidis, and K.C. Siamopoulos Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial Kidney Int 66 2004 753 760
17. J.S. Kaufman, D.J. Reda, and C.L. Fye Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients N Engl J Med 339 9 1998 578 583
18. H. Klinkmann, L. Wieczorek, and P. Scigalla Adverse events of subcutaneous recombinant human erythropoietin therapy: results of a controlled multicenter European study Artif Organs 17 4 1993 219 225
19. S. Kuriyama, H. Tomonari, H. Yoshida, T. Hashimoto, Y. Kawaguchi, and O. Sakai Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients Nephron 77 2 1997 176 185
20. A. Levin, O. Djurdjev, and C. Thompson Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD Am J Kidney Dis 46 2005 799 811
21. F. Locatelli, C.A. Baldamus, and G. Villa Once-weekly compared with three-times-weekly subcutaneous epoetin beta: results from a randomized, multicenter, therapeutic-equivalence study Am J Kidney Dis 40 1 2002 119 125
22. I.C. Macdougall, R.M. Temple, and J.T.C. Kwan Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial Nephrol Dial Transplant 22 2007 784 793
23. N. Muirhead, D.N. Churchill, and M. Goldstein Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease Am J Nephrol 12 5 1992 303 310
24. A.R. Nissenson, S.K. Swan, and J.S. Lindberg Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients Am J Kidney Dis 40 1 2002 110 118
25. R. Provenzano, S. Bhaduri, and A.K. Singh Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT Study Clin Nephrol 64 2 2005 113 123 (Pubitemid 41079007)
26. S.D. Roger, L.P. McMahon, and A. Clarkson Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial J Am Soc Nephrol 15 2004 148 156
27. J. Rossert, A. Levin, and S.D. Roger Effect of early correction of anemia on the progression of CKD Am J Kidney Dis 47 2006 738 750
28. D. Roth, R.D. Smith, and G. Schulman Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients Am J Kidney Dis 24 5 1994 777 784
29. M. Tonelli, S. Klarenbach, and B. Manns Residence location and likelihood of kidney transplantation CMAJ 175 5 2006 478 482
30. Canadian Organ Replacement Registry Treatment of End-Stage Organ Failure in Canada 2002 and 2003 2005 Canadian Institutes of Health Information Ottawa, Canada
31. S. Gao, B.J. Manns, and B. Culleton Access to health care among status Aboriginal people with chronic kidney disease CMAJ 179 10 2008 1007 1012
32. L.M. Moist, R.N. Floey, and B.J. Barrett Clinical practice guidelines for evidence-based use of erythropoietic-stimulating agents Kidney Int Suppl 110 2008 S12 S18
33. M. Tonelli, S. Klarenbach, N. Wiebe, F. Shrive, B. Hemmelgarn, and B. Manns Erythropoiesis-Stimulating Agents for Anemia of Chronic Kidney Disease: Systematic Review and Economic Evaluation 2008 Canadian Agency for Technology and Drugs in Health Ottawa, Canada Technology report no. 106
34. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen TREAT Investigators A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 21 2009 2019 2032
35. R.A. Wolfe, V.B. Ashby, and E.L. Milford Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant N Engl J Med 341 23 1999 1725 1730
36. R. Schall Estimation of generalized linear models with random effects Biometrika 78 1991 719 727
37. G.W. Torrance Utility approach to measuring health related quality of life J Chronic Dis 40 6 1987 593 600
38. B. Manns, J.A. Johnson, K. Taub, G. Mortis, W.A. Ghali, and C. Donaldson Quality of life in patients treated with hemodialysis or peritoneal dialysis: what are the important determinants? Clin Nephrol 60 5 2003 341 351
39. F.M. Clement, S.K. Klarenbach, M. Tonelli, J. Johnson, and B.J. Manns The impact of selecting a high hemoglobin target on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis Arch Intern Med 169 12 2009 1104 1112
40. A. Laupacis, P. Keown, and N. Pus A study of the quality of life and cost-utility of renal transplantation Kidney Int 50 1 1996 235 242
41. D.G. Fryback, W.F. Lawrence, P.A. Martin, R. Klein, and B.E.K. Klein Predicting quality of well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study Med Decis Making 17 1997 1 9
42. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen TREAT Investigators A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 21 2009 2019 2032
43. E. Ritz, M. Laville, R.W. Bilous, D. O'Donoghue, A. Scherhag, U. Burger ACORD Investigators Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study Am J Kidney Dis 49 2007 194 207
44. H. Lee, B. Manns, and K. Taub Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access Am J Kidney Dis 40 3 2002 611 622
45. M. Amin, D. Fergusson, and K. Wilson The societal unit cost of allogenic red blood cells and red blood cell transfusion in Canada Transfusion 44 2004 1479 1486
46. Alberta Blue Cross Alberta Health and Wellness drug benefit list criteria for special authorization of select drug products http://www.ab.bluecross.ca/ dbl/pdfs/ahwdbl-sec3.pdf Accessed August 10, 2007
47. B. Manns, C.J. Doig, and H. Lee Cost of acute renal failure requiring dialysis in the intensive care unit: clinical and resource implications of renal recovery Crit Care Med 31 2 2003 449 455
48. Statistics Canada Consumer Price Index for Canada 2006 Statistics Canada Ottawa, Canada
49. B. Manns, D. Meltzer, K. Taub, and C. Donaldson Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care Health Econ 12 11 2003 949 958
50. Centers for Medicare & Medicaid Services Medicare Claims Processing Manual 2008 Centers for Medicare & Medicaid Services Baltimore, MD
51. A. Shander, A. Hofmann, S. Ozawa, O.M. Theusinger, H. Gombotz, and D.R. Spahn Activity-based costs of blood transfusions in surgical patients at four hospitals Transfusion 50 4 2010 753 765
52. World Bank World Development Indicators 2010 2010 The World Bank Group Washington, DC
53. K.W. Wyrwich, J.A. Spertus, K. Kroenke, W.M. Tierney, A.N. Babu, and F.D. Wolinsky Heart Disease Expert Panel Clinically important differences in health status for patients with heart disease: an expert consensus panel report Am Heart J 147 2004 615 622
54. K.W. Wyrwich, W.E. Tierney, A.N. Babu, K. Kroeke, and F.D. Wolinsky A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease Health Serv Res 40 2 2005 577 592
55. M. Gold Panel on cost-effectiveness in health and medicine Med Care 34 suppl 12 1996 DS197 DS199
56. A. Laupacis, D. Feeny, A.S. Detsky, and P.X. Tugwell Tentative guidelines for using clinical and economic evaluations revisited CMAJ 148 6 1993 927 929
57. National Institute for Health and Clinical Excellence Social Value Judgements: Principles for the Development of NICE Guidance. 2nd ed http://www.nice.org.uk/media/C18/30/SVJ2PUBLICATION2008.pdf Accessed November 10, 2008
58. F.C. Clement, A. Harris, J.J. Li, K. Yong, K.M. Lee, and B.J. Manns Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada JAMA 302 13 2009 1437 1443
59. D.C. Harris, J.R. Chapman, J.H. Stewart, S. Lawrence, and S.D. Roger Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis Aust N Z J Med 21 5 1991 693 700
60. B. Leese, J. Hutton, and A. Maynard The Costs and Benefits of the Use of Erythropoietin in the Treatment of Anaemia Arising from Chronic Renal Failure: A European Study 1990 Centre for Health Economics York
61. B. Leese, J. Hutton, and A. Maynard A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries Pharmacoeconomics 1 5 1992 346 356